Compounds > gefitinib
Page last updated: 2024-09-03

gefitinib and Carcinoma, Adenosquamous

gefitinib has been researched along with Carcinoma, Adenosquamous in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (12.50)29.6817
2010's7 (87.50)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lin, B; Shao, L; Song, Z; Zhang, Y1
Barinow-Wojewódzki, A; Krawczyk, P; Kucharczyk, T; Milanowski, J; Milecki, P; Powrózek, T; Ramlau, R; Sura, S; Szumiło, J; Szyszka-Barth, K; Walczyna, B; Wojas-Krawczyk, K1
Aoyama, A; Chen, F; Date, H; Menju, T; Omasa, M; Sato, M; Sato, T; Sonobe, M; Yamada, T; Yokoyama, Y1
Endo, M; Kaira, K; Kaira, R; Kenmotsu, H; Murakami, H; Naito, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, K; Takahashi, T; Tsuya, A; Yamamoto, N1
Goya, S; Hatazawa, J; Hirata, H; Inoue, A; Kawase, I; Kida, H; Kijima, T; Kumagai, T; Kumanogoh, A; Nagatomo, I; Okumura, M; Shimosegawa, E; Tachibana, I; Takahashi, R; Takeda, Y; Yoshida, M1
Gemma, A; Gemmah, A; Hagiwara, K; Harada, M; Inoue, A; Isobe, H; Kobayashi, K; Kudoh, S; Maemondo, M; Minegishi, Y; Morikawa, N; Nukiwa, T; Oizumi, S; Okinaga, S; Tanaka, T1
Iwanaga, K; Kimura, S; Mori, D; Nakamura, T; Sueoka-Aragane, N1
Chang, WC; Chen, YR; Chen, YT; Fu, YN; Huang, SF; Ku, YC; Kuo, HP; Li, LH; Lin, YF; Liu, HP; Tsai, HY; Tsai, SF; Wu, YC1

Trials

1 trial(s) available for gefitinib and Carcinoma, Adenosquamous

ArticleYear
First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:9

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Feasibility Studies; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Prognosis; Quinazolines; Survival Rate

2012

Other Studies

7 other study(ies) available for gefitinib and Carcinoma, Adenosquamous

ArticleYear
Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.
    Journal of the Chinese Medical Association : JCMA, 2013, Volume: 76, Issue:9

    Topics: Antineoplastic Agents; Carcinoma, Adenosquamous; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Treatment Outcome

2013
EGFR gene mutations in patients with adenosquamous lung carcinoma.
    Asia-Pacific journal of clinical oncology, 2014, Volume: 10, Issue:4

    Topics: Aged; Antineoplastic Agents; Carcinoma, Adenosquamous; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Poland; Polymerase Chain Reaction; Quinazolines; Remission Induction; Smoking

2014
Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations.
    International journal of clinical oncology, 2015, Volume: 20, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Postoperative Period; Quinazolines; Time Factors; Treatment Outcome

2015
Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports.
    Cancer science, 2011, Volume: 102, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Treatment Outcome

2011
Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jan-01, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Adenosquamous; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Mutation; Positron-Emission Tomography; Prognosis; Quinazolines; Radiopharmaceuticals; Survival Rate; Tomography, X-Ray Computed

2012
The long-term survival of a patient with adenosquamous lung carcinoma harboring EGFR-activating mutations who was treated with gefitinib.
    Internal medicine (Tokyo, Japan), 2012, Volume: 51, Issue:19

    Topics: Amino Acid Substitution; Antineoplastic Agents; Carcinoma, Adenosquamous; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Middle Aged; Mutation; Mutation, Missense; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion

2012
High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Dec-15, Volume: 10, Issue:24

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Phosphorylation; Quinazolines; Sequence Homology, Nucleic Acid; Taiwan

2004